Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

Bibliography

• Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102(1):37-46
   PubMed Web of Science ®Google Scholar
• Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 2001;11(2):105-17
   PubMed Web of Science ®Google Scholar
• Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001;21(12):4016-31
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008;19(2):99-113
   PubMed Web of Science ®Google Scholar
• Akashi Y, Okamoto I, Iwasa T, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008;98(4):749-55
   PubMed Web of Science ®Google Scholar
• Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003;22(2):237-52
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-55
   PubMed Web of Science ®Google Scholar
• Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004;90(12):2250-5
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301-11
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer(NSCLC): data from the FLEX study. J Clin Oncology 2009;27(15s): abstract 8007
   Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47(1):9-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56(2):317-26
   PubMed Web of Science ®Google Scholar
• Orditura M, De Vita F, Galizia G, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009;21(4):1023-8
   PubMed Web of Science ®Google Scholar
• Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol 2007;25(18s):4134
   Google Scholar
• Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003;26(2):139-48
   PubMed Web of Science ®Google Scholar
• Winquist E, Nabid A, Sicheri D, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002;21: abstract 926
   Google Scholar
• Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22(9):1646-54
   PubMed Web of Science ®Google Scholar
• Rojo F, Gracias E, Villena N, et al. Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO foundation study. J Clin Oncol 2008;26(May 20 Suppl): abstract 6070
   PubMedGoogle Scholar
• Reddy BK, Vidyasagar M, Shenoy K, et al. BIOMAb EGFRTM (Nimotuzumab/h-r3) in combination with standard of care in squamous cell carcinoma of head and neck (SCCHN). Int J Radiat Oncol Biol Phys 2007;69(3):S450
   Google Scholar
• Brade AM, Magalhaes J, Siu L, et al. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors. J Clin Oncol 2007;25(18S, Part 1, June 20 Suppl): abstract 14030
   Google Scholar
• Bebb DG, Brade AM, Smith C, et al. Preliminary results of an escalating dose phase I clinical trail of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. J Clin Oncol 2008;26 (May 20 Suppl): abstract 3037
   Google Scholar
• Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006;5(4):375-9
   PubMed Web of Science ®Google Scholar
• Crombet T, Figueredo J, Salomón MT, et al. Use the humanized anti-EGFR MAb (nimotuzumab) and irradiation for the treatment of high grade glioma patients. EORTC-NCI-AACR Annual Meeting, Geneva, 2008. Available from: http://www.ymbiosciences.com/upload_files/nimo_poster_EORTC2008_glioma.pdf [Last accessed 23 June 2009]
   Google Scholar
• Bode U, Buchen S, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2007;25(18S, Part 1, June 20 Suppl): abstract 2006
   Google Scholar
• Bode U, Windelberg M, Massimino M, et al. Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol 2008;26(May 20 Suppl): abstract 2058
   Google Scholar
• Macias A, Neninger E, Santiesteban E, et al. Preliminary results of a phase II clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer (NSCLC) and unresectable brain metastases. EORTC-NCI-AACR Annual Meeting, Geneva, 2008. Available from: http://www.ymbiosciences.com/upload_files/nimo_poster_EORTC2008_NSCLC.pdf [Last accessed 22 June 2009]
   Google Scholar
• Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997;3(1):71-81
   PubMedGoogle Scholar
• Arteaga ME, Ledón N, Casacó A, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody Nimotuzumab. Cancer Biol Ther 2007;6(9):1390-5
   PubMed Web of Science ®Google Scholar
• Talavera A, Martínez C, Friemann R, et al. Modeling the interaction between the anti-tumor antibody h-R3 and its target, the epidermal growth factor receptor 2007. Available from: www.ymbiosciences.com/upload_files/pub_nimo_oslo_2007_talavera.pdf [Last accessed 22 June 2009]
   Google Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002;101(6):567-75
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61(13):5090-101
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007;83(3):238-48
   PubMed Web of Science ®Google Scholar
• Li X, Lu Y, Liang K, et al. Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 2008;7(5):1207-17
   PubMed Web of Science ®Google Scholar
• Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998;46(3):167-73
   PubMed Web of Science ®Google Scholar
• Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007;26(6):423-31
   PubMed Web of Science ®Google Scholar
• Rivera F, Salcedo M, Vega N, et al. Current situation of zalutumumab. Expert Opin Biol Ther 2009;9(5):667-74
   PubMed Web of Science ®Google Scholar
• Tikhomirov I, Garrido G, Yang E, et al. Bivalent binding properties of epidermal growth factor receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profiles. AACR Cancer Clinical Trials and Personalized Medicine, 2008(abstract A36). Available from: http://www.ymbiosciences.com/upload_files/poster_nimo_AACR_Translational_Med_2008.pdf [Last accessed 22 June 2009]
   Google Scholar
• Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008;26(24):4001-11
   PubMed Web of Science ®Google Scholar
• Pendharkar D, Gupta S, Pal MK, et al. Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy-A study of toxicity profile and tolerance. J Clin Oncol 2007;25 (18S June 20 Suppl): abstract 14151
   Google Scholar
• Soriano J, Batista N, Lima M, et al. Phase I clinical study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally-advanced breast cancer. Preliminary results. Eur J Cancer Suppl 2007;5(4):116
   Google Scholar
• Shah AC, Chen E, Jonker D, et al. A Phase II clinical trial of nimotuzumab, an EGFR monoclonal antibody (MAb), in metastatic colorectal cancer (mCRC). ASCO GI symposium proceedings: abstract 358 (Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10679)
   Google Scholar
• Reddy BK, Vidyasagar MS, Shenoy K, et al. Nimotuzumab (h-R3) in combination with chemoradiotherapy & radiotherapy in the treatment of squamous cell carcinoma of head & neck (SCCHN) 2007. Available from: http://astro2007.abstractsnet.com/handouts/500467_Biocon_h-R3.pdf [Last accessed 22 June 2009]
   Google Scholar
• Reddy BK, Vidyasagar MS, Koteshwar R, et al. A Phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. J Clin Oncol 2009;27 (15s Suppl): abstract 6041
   Google Scholar
• Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;5(4):657-70
   Google Scholar
• Garrido G, Rabasa A, Gracia E, et al. Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells. AACR 100th Annual Meeting, 2009 (abstract 2763). Available from: http://www.ymbiosciences.com/upload_files/nimo_poster_AACR2009.pdf [Last accessed 22 June 2009]
   Google Scholar
• Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;5:387-94
   Google Scholar
• Giusti RM, Cohen MH, Keegan P, Pazdur R. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist 2009;4(3):284-90
   Google Scholar